HTR2B and amyotrophic lateral sclerosis: Although treatment with a 5-HT2B receptor agonist did not improve the ultimate disease outcome in ALS mice, it was found to modulate microglial gene expression, slowing the progression of ALS, suggesting that targeting 5-HT2B might be a potential therapeutic approach [142].